ZRS Pharmaceuticals

ZRS Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative therapies for dermatological and autoimmune conditions. The company's primary focus is on the development of highly selective, topical small molecule inhibitors, particularly targeting the Janus kinase (JAK) pathway. Its lead candidate, ZRS-062, is a potent topical JAK inhibitor currently being evaluated in clinical trials for indications such as atopic dermatitis and psoriasis. ZRS Pharmaceuticals aims to address significant unmet medical needs in the field of medical aesthetics and chronic inflammatory skin diseases through its robust R&D pipeline. The company was founded by industry veterans with extensive experience in global pharmaceutical R&D and commercialization. By focusing on topical delivery, ZRS seeks to provide effective local treatment while minimizing the systemic safety concerns often associated with oral JAK inhibitors.